SEARCH

SEARCH BY CITATION

References

  • Andersson J. L., Nomikos G. G., Marcus M., Hertel P., Mathé J. M. & Svensson T. H. (1995) Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn-Schmiedeberg's Arch. Pharmacol. 352, 374385.
  • Araneda R. & Andrade R. (1991) 5-Hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40, 399412.
  • Arborelius L., Chergui K., Murase S., Nomikos G. G., Hook B. B., Chouvert G., Hacksell U. & Svensson T. H. (1993) The 5-HT1A receptor selective ligands, R (+)-8-OH-DPAT and (S)-UH 301, differentially affect the activity of midbrain dopamine neurons. Naunyn-Schmiedeberg's Arch. Pharmacol. 347, 353362.
  • Arnt J. & Skarsfeldt T. (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18, 63101.DOI: 10.1016/s0893-133x(97)00112-7
  • Ashby C. R., Edwards E. & Wang R. Y. (1994) Electrophysiological evidence for a functional interaction between 5-HT1a and 5-HT2a receptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse 17, 173181.
  • Backus L. I., Sharp T. & Grahame-Smith D. G. (1990) Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors. Br. J. Pharmacol. 100, 793799.
  • Brody D., Adler L. A., Kim T., Angrist B. & Rotrosen J. (1990) Effects of buspirone in seven schizophrenic subjects. J. Clin. Psychopharmacol. 10, 6869.
  • Bymaster F. P., Calligaro D. O., Falcone J. F., Marsh R. D., Moore N. A., Tye N. C., Seeman P. & Wong D. T. (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 8796.DOI: 10.1016/0893-133x(94)00129-n
  • Cartmell J., Perry K. W., Salhoff C. R., Monn J. A. & Schoepp D. D. (2000) The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat. J. Neurochem. 75, 11471154.
  • Daly D. A. & Moghaddam B. (1993) Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci. Lett. 152, 6164.
  • Glennon R. A., Raghupathi R., Bartyzel P., Teitler M. & Leonhardt S. (1992) Binding of phebylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem. 35, 734740.
  • Gobert A. & Millan M. J. (1999) Serotonin (5-HT) 2A receptor activation enhances dialysis levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 38, 315317.DOI: 10.1016/s0028-3908(98)00188-9
  • Gobert A., Rivet J. M., Audinot C., Newman-Tancredi A. N., Cistarelli L. & Millan M. J. (1998) Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 84, 413429.DOI: 10.1016/s0306-4522(97)00565-4
  • Goff D. C., Midha K. K., Brotman A. W., McCormick S., Waites M. & Amico E. T. (1991) An open trial of buspirone added to neuroleptics in schizophrenic patients. J. Clin. Psychopharmacol. 11, 193197.
  • Hertel P., Nomikos G. G., Iurlo M. & Svensson T. H. (1996) Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology 124, 7486.
  • Hertel P., Nomikos G. G. & Svensson T. H. (1997) risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine. Br. J. Pharmacol. 122, 16391646.
  • Hertel P., Fagerquist M. V. & Svensson T. H. (1999) Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by α2 adrenoceptor blockade. Science 286, 105107.DOI: 10.1126/science.286.5437.105
  • Ichikawa J. & Meltzer H. Y. (1997) Ziprasidone, a new antipsychotic, produces a preferential increase in extracellular dopamine (DA) utilization in the medial prefrontal cortex (mPFC). Soc. Neurosci. Abstract. 23, 161.7.
  • Ichikawa J. & Meltzer H. Y. (1999a) R (+)-8-OH-DPAT, a serotonin1A receptor agonist, potentiated S (-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J. Pharmacol. Exp. Ther. 291, 12271232.
  • Ichikawa J. & Meltzer H. Y. (1999b) Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur. Arch. Psychiat. &. Clin. Neurosci. 249, S90S98.
  • Ichikawa J. & Meltzer H. Y. (2000) The effect of serotonin1A receptors on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res. 858, 252263.DOI: 10.1016/s0006-8993(99)02346-x
  • Ichikawa J., Kuroki T., Dai J. & Meltzer H. Y. (1998) Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur. J. Pharmacol. 351, 171.
  • Khawaja X., Evans N., Reilly Y., Ennis C. & Minchin M. C. W. (1995) Characterization of the binding of [3H]WAY-100635, a novel 5-hydroxytryptamine1A receptor antagonist, to rat brain. J. Neurochem. 64, 27162726.
  • Kuroki T., Ichikawa J., Dai J. & Meltzer H. Y. (1996) R (+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex. Brain Res. 743, 357361.DOI: 10.1016/s0006-8993(96)01111-0
  • Kuroki T., Meltzer H. Y. & Ichikawa J. (1999) Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288, 774781.
  • Lejeune F., Newman-Tancredi A., Audinot V. & Millan M. J. (1997) Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino) tetralin at human (h) D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotonergic and dopaminergic neurons in rats. J. Pharmacol. Exp. Ther. 280, 12411249.
  • Li X.-M., Perry K. W., Wong D. T. & Bymaster F. P. (1998) Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 136, 153161.DOI: 10.1007/s002130050551
  • Liégeois J. F., Ichikawa J., Bonaccorso S. & Meltzer H. Y. (2000) M100907, a 5-HT2A receptor antagonist, potentiates haloperidol-induced dopamine (DA) release in the medial prefrontal cortex (mPFC), but inhibits that in the nucleus accumbens (NAC). Soc. Neurosci. Abst. 26, 143.15.
  • Leysen J. E., Janssen P. M. F., Schotte A., Luyten W. H. M. L. & Megens A. A. H. P. (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacol. 112, S40S54.
  • Matsuda T., Yoshikawa T., Suzuki M., Asano S., Somboonthum P., Takuma K., Nakano Y., Morita T., Nakasu Y., Kim H. S., Egawa M., Tobe A. & Baba A. (1995) Novel benzodioxan derivative, 5-(3-[(2S)-1,4-benzodioxan-2- ylmethyl) amino]propoxy)-1,3-benzodioxole HCl (MKC-242), with a highly potent and selective agonist activity at rat central serotonin1A receptors. Jpn. J. Pharmacol. 69, 357366.
  • Matsuyama S., Nei K. & Tanaka C. (1996) Regulation of glutamate release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus. Brain Res. 728, 175180.DOI: 10.1016/s0006-8993(96)00395-2
  • Meltzer H. Y. & McGurk S. R. (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25, 233255.
  • Meltzer H. Y., Matsubara S. & Lee J.-C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of D-1, D-2, and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238246.
  • Millan M. J., Canton H. & Lavielle G. (1992) Targeting multiple serotonin receptors: mixed 5-HT1A agonists/5-HT1C/2 antagonists as therapeutic agents. Drug News Perspective 5, 397406.
  • Millan M. J., Rivet J.-M., Audinot V., Gobert A., Lejeune F., Brocco M., Newman-Tancredi A., Maurel-Remy S. & Bervoets K. (1995) Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo. J. Pharmacol. Exp. Ther. 273, 14181427.
  • Moghaddam B. & Bunney B. S. (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54, 17551760.
  • Newman-Tancredi A., Gavaudan S., Conte C., Chaput C., Touzard M., Verriele L., Audinot V. & Millan M. J. (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPγS binding study. Eur. J. Pharmacol. 355, 245256.DOI: 10.1016/s0014-2999(98)00483-x
  • Paxinos G. & Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
  • Pazos A., Cortes R. & Palacios J. M. (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res. 346, 231249.
  • Pompeiano M., Palacios J. M. & Mengod G. (1992) Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J. Neurosci. 12, 440453.
  • Prisco S., Pagannone S. & Esposito E. (1994) Classification of typical and atypical antipsychotic drugs on the basis of D-1, D-2, and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 271, 8390.
  • Rollema H., Lu Y., Schmidt A. W. & Zorn S. H. (1997) Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur. J. Pharmacol. 338, R3R5.DOI: 10.1016/s0014-2999(97)81951-6
  • Rollema H., Lu Y., Schmidt A. W., Sprouse J. & Zorn S. H. (2000) 5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in rat prefrontal cortex. Biol. Psychiatry 48, 229237.DOI: 10.1016/s0006-3223(00)00850-7
  • Sakaue M., Somboonthum P., Nishihara B., Koyama Y., Hashimoto H., Baba A. & Matsuda T. (2000) Postsynaptic 5-hydroxytryptamine1A receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br. J. Pharmacol. 129, 10281034.
  • Santiago M. & Westerink B. H. C. (1991a) The regulation of dopamine release from nigrostriatal neurons in conscious rats: The role of somatodendritic autoreceptors. Eur. J. Pharmacol. 204, 7985.
  • Santiago M. & Westerink B. H. C. (1991b) Characterization and pharmacological responsiveness of dopamine release recorded by microdialysis in the substantia nigra of conscious rats. J. Neurochem. 57, 738747.
  • Schotte A., Janssen P. F. M., Gommeren W., Luyten W. H. M. L., Van Gompel P., De Lesage A. S., Loore K. & Leysen J. E. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124, 5773.
  • Seeger T. F., Seymour P. A., Schmidt A. W., Zorn S. H., Schulz D. W., Lebel L. A., McLean S., Guanowsky V., Howard H. R., Lowe J. A. & Heym J. (1997) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. 275, 113.
  • Shimizu H., Karai N., Hirose A., Tatsuno T., Tanaka H., Kumasaka Y. & Nakamura M. (1988) Interaction of SM-3997 with serotonin receptors in rat brain. Jpn. J. Pharmacol. 46, 311314.
  • Stockmeier C. A., DiCarlo J. J., Zhang Y., Thompson P. & Meltzer H. Y. (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J. Pharmacol. Exp. Ther. 266, 13741384.
  • Sumiyoshi T., Matsui M., Yamashita I., Nohara S., Uehara T., Kurachi M. & Meltzer H. Y. (2000) Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J. Clin. Psychopharmacol. 20, 386388.
  • Tanda G., Caroni E., Frau R. & Di Chiara G. (1994) Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology 115, 288.
  • Ugedo L., Grenhoff J. & Svensson T. H. (1989) Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98, 4550.
  • Volonté M., Monferini E., Cerutti M., Fodritto F. & Borsini F. (1997) BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J. Neurochem. 69, 182190.
  • Wadenberg M. L., Salmi P., Jimenez P., Svensson T. & Ahlenius S. (1996) Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat. Eur. J. Neuropsychopharmacol. 6, 305310.
  • Wadenberg M. L., Hicks P. B., Richter J. T. & Young K. A. (1998) Enhancement of antipsychotic-like properties of raclopride in rats using the selective serotonin2a receptor antagonist MDL 100,907. Biol. Psychiatry 44, 508515.DOI: 10.1016/s0006-3223(97)00424-1
  • Willins D. L. & Meltzer H. Y. (1997) Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J. Pharmacol. Exp. Ther. 282, 699706.
  • Zhang W. & Bymaster F. P. (1999) The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacol. 141, 267278.